NXL ▼ -2.4% - Nexalin Technology, Inc. $NXL NXLIW - Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer’s Pilot Study Nexalin Technology announced a secondary analysis of its clinical trial data showing previously unreported improvements in memory, comprehension, and language function in Alzheimer's patients, with results expected to inform the design of an upcoming U.S. pilot study. The stock declined 2.4% despite the positive clinical findings, suggesting investors may have focused on the preliminary nature of the secondary analysis or questions about the path to commercialization rather than the efficacy data itself. 03-SEP-2026 08:30 AM ET